Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure
Anthony J. Garcia‐Prats, Susan E. Purchase, Muhammad Osman, Heather R. Draper, H. Simon Schaaf, Lubbe Wiesner, Paolo Denti, Anneke C. Hesseling
Antimicrobial Agents and Chemotherapy · 2019-01
Abstract
This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children ( n = 109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling.
MeSH terms
- Levofloxacin
- Pharmacokinetics
- Dosing
- Medicine
- Bioavailability
- Pharmacology
- Tuberculosis